Extension Program for Bay 43-9006

Status Completed

Clinical Trial Summary

The study was designed to allow for the continuation of treatment with Sorafenib as a single agent to those patients who participated in a previous Sorafenib study that had reached its designated end-date and who were, in the opinion of the Investigator and the Sponsor, still benefiting from treatment.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00657254
Study type	Interventional
Source	Bayer
Contact
Status	Completed
Phase	Phase 2
Start date	December 2002
Completion date	June 2005

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01441115` - ECI301 and Radiation for Advanced or Metastatic Cancer	Phase 1
Terminated	`NCT03257722` - Pembrolizumab + Idelalisib for Lung Cancer Study	Phase 1/Phase 2
Recruiting	`NCT01201096` - Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)	N/A
Completed	`NCT01206530` - FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer	Phase 1/Phase 2
Completed	`NCT01199822` - Study of the Safety and Pharmacokinetics of IMC-3G3 in Japanese Patients With Solid Tumors	Phase 1
Completed	`NCT00377936` - EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas	Phase 2
Completed	`NCT00313859` - Phase II Study of Simvastatin Plus Irinotecan, Fluorouracil, and Leucovorin(FOLFIRI) for Metastatic CRC	Phase 2
Recruiting	`NCT05095207` - Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer	Phase 1/Phase 2
Active, not recruiting	`NCT04392479` - TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.	Phase 3
Recruiting	`NCT04808466` - Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy	Phase 2
Terminated	`NCT03652493` - Trial Evaluating the Efficacy of CARBOPLATIN in Metastatic Prostate Cancer With Gene Alterations in the Homologous Recombination Pathway	Phase 2
Not yet recruiting	`NCT04845490` - Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy	Phase 2
Recruiting	`NCT05061082` - Genomic Evolution of Metastasis in Gastric Cancer
Not yet recruiting	`NCT06055764` - Role of FDG PET/CT in Patients With Metastasis of Unknown Origin
Terminated	`NCT02796729` - CEST- Glucose Enhanced MRI for Metastatic Brain Tumours	Phase 2
Withdrawn	`NCT01157039` - A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin	Phase 2
Terminated	`NCT01000948` - A Safety Study of ZD4054 in Prior Chemotherapy Treated Patients With Metastatic Hormone-resistant Prostate Cancer	Phase 2
Terminated	`NCT01613482` - TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention	Phase 3
Withdrawn	`NCT00244348` - Hepatic Artery Infusion With Oxaliplatin	Phase 1/Phase 2
Recruiting	`NCT04416165` - Comparison of FDG and FAPI in Patients With Various Types of Cancer	N/A